论文部分内容阅读
目的用普米克令舒与沐舒坦雾化吸入评价其安全性与疗效。方法收集在我院2008年6月至2009年6月期间住院的毛细支气管炎的患儿平均年龄在24个月以下70例的临床资料,按入院顺序随机分成治疗组、对照组各35例。在综合治疗的同时,对两组患儿的症状体征变化进行评估治疗,并组加用沐舒坦、普米克令舒雾化吸入。结果对照组均明显低于治疗组,经统计学试验差异有统计学意义(P<0.01)。结论普米克令舒和沐舒坦雾化吸入对毛细支气管炎患儿的治疗方便安全疗效好有明显的效果。
Objective To evaluate the safety and efficacy of pulmicort respules and mucosolvan inhalation. Methods The clinical data of 70 children with bronchiolitis admitted to our hospital from June 2008 to June 2009 were randomly divided into treatment group and control group with 35 cases in each group. In the comprehensive treatment at the same time, the two groups of children with signs and symptoms were evaluated treatment, and the group plus mucosolvan, pulmicort respiration inhalation. The results of the control group were significantly lower than the treatment group, the statistical difference was statistically significant (P <0.01). Conclusion Pulmicort respules and mucosolvan inhalation have obvious effect on the treatment of bronchiolitis in children with convenient and safe treatment.